
Aclaris Therapeutics to Present New Data on Atopic Dermatitis Drug at EADV Congress
WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) announced that new findings from its Phase 2a trial of ATI-2138, an investigational oral therapy for moderate-to-severe atopic dermatitis, will be featured …
Aclaris Therapeutics to Present New Data on Atopic Dermatitis Drug at EADV Congress Read More